Steven Cohen Revance Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 17,100 shares of RVNC stock, worth $43,947. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,100
Previous 17,100
-0.0%
Holding current value
$43,947
Previous $43,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RVNC
# of Institutions
204Shares Held
84.3MCall Options Held
490KPut Options Held
147K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$15.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...